Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs

Abstract

Methods and compositions are provided for protecting or enhancing the function or viability of effector cells, tissues, organs or body parts in mammals, including humans, in vivo, in situ or ex vivo, i.e. by systemic or local administration of recombinant tissue protective cells Factors such as modulators of erythropoietin receptor activity.

Description

This application claims priority to U.S. Provisional Patent Application No. 60 / 392,455, filed July 1, 2002, and to U.S. Provisional Patent Application No. 60 / 393,423, filed July 3, 2002, all of which are The contents are incorporated herein by reference in their entirety. 1 Introduction The present invention relates to a mutant protein recombinant tissue protective cytokine with one or more amino acid substitutions for protecting, maintaining, enhancing or restoring the function or viability of mammalian effector cells and their related cells, tissues and organs, and relates to a recombinant tissue protective cytokine comprising said Pharmaceutical compositions of cytokines. This includes protecting excitable tissues such as neurons and cardiac tissue from neurotoxins, hypoxia, and other adverse stimuli, and includes enhancing excitable tissue function, eg, for promoting learning and memory. The present invention also relates to compositions using mu...

AI Technical Summary

Problems solved by technology

Although studies have established that intracranial injection of erythropoietin protects neurons from hypoxic neuronal injury, intracranial administration is impractical for therapeutic applications, especially in normal individuals, and unacceptable route of administration

Images